Despite concerns around the global political and economic landscape, the biopharmaceutical industry still maintains a favourable mid-to long-term outlook with a promising future for revenues.
The industry’s clinical pipeline remains robust, with a growing number of new molecular entities in development. Increasing complexity of molecules entering the clinical pipeline drives demand for experienced partners who can support clients, reduce investment risk and accelerate time to market.
For an overview of the key trends, current state of the market and the future outlook for CRO, CDMO, Packaging and Distribution service sectors, read PharmaVentures’ new report, Pharma Services Overview.
Pharma Services Overview